About Neodyne Biosciences
Neodyne was founded in 2007 at Stanford University. In 2008, the company was spun out of Stanford and is currently being led by an experienced team of medical device industry executives. Neodyne is located in the heart of Silicon Valley with access to a wealth of expertise in medical technology research and development and venture capital.
Our active founders include:
Geoffrey Gurtner, M.D., FACS
Professor of Surgery at Stanford University, Division of Plastic Surgery
Michael Longaker, M.D., FACS
Professor Department of Surgery, Stanford University Medical Center, Director, Program in Regenerative Medicine
Paul Yock, M.D.
Director of the Biodesign Program, Co-Chair of Bioengineering, Professor of Medicine at Stanford University, Interventional cardiologist
Neodyne Biosciences is an evidence-based company developing and commercializing innovative tissue repair devices to minimize scar formation, restoring both function and aesthetic appearance. Utilizing patented technology, we believe that effective scar minimization will become a reality for many of those undergoing surgical procedures.
“Beyond improving aesthetic appearances, we at Neodyne are dedicated to improving patients’ lives—one scar at a time. As a mom I can empathize with other moms who worry about a playground cut leaving its lifetime mark. I understand the mental concern an untreated C-section scar can cause as you embark on restoring yourself after birth. I appreciate the desire to heal as gracefully as possible after any and all surgical procedures. It just helps you feel like you again!– and this is what inspires us each and every day.”
Kelley Lipman, President, Chief Commercial Officer
Scar formation post-surgery is a significant clinical problem that can lead to disability and disfigurement. Approximately 80 million surgical procedures are performed in the US each year. Additionally, there are millions of existing unwanted scars that could be revised and treated if there were an effective and durable solution. The annual US economic burden of this problem has been conservatively estimated at more than four billion dollars.